PROCTER-&-GAMBLE
Today, at the ChangeNOW online Live Talk , Procter & Gamble’s (NYSE:PG) Ariel laundry detergent brand will announce an expanded 2030 Brand Ambition focused on “reinventing clean to decarbonise laundry across its entire value chain.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210311005112/en/
To do this Ariel has focused on ensuring it can deliver a superior clean in colder water, whilst also committing the brand’s voice to encourage small habit changes such as lowering wash temperatures. The brand is also working towards establishing a sustainable supply chain with industry and suppliers, as well as partnering for innovation.
The first milestone in this journey is the roll out of Ariel’s pan-European consumer engagement campaign, “Every Degree Makes a Difference” in content partnership with National Geographic Creative Works, to demonstrate that through turning down our washing cycle temperature we can together reduce greenhouse gas emissions. The campaign, which is already launched in Germany and is coming to France this week, seeks to achieve a five degree drop in average wash temperatures in Europe by 2025.
Ariel’s Life Cycle Assessment (LCA) found that on average in Europe 60% of the environmental footprint of laundry comes when the product is being used, mainly from the energy used to heat the water. Lowering the wash temperature is the single most important thing we can all do to reduce the environmental impact of laundry. Through short films and emotive images created by National Geographic Creative Works, the campaign highlights the impact of global warming on the arctic regions and brings to life that we can all make an impact on our planet.
As part of its 2030 Ambition, Ariel is pursuing a sustainable supply chain through analysing the ingredients with highest CO2 potential in its formula and exploring alternative sourcing, working closely with its suppliers. The brand is looking into partnerships to find new solutions that help further decarbonise its value chain, including novel sources of carbon and new models for recycling.
“Serving five billion people gives our brands the unique opportunity to promote conversations, influence attitudes and change behaviour,” comments Virginie Helias, Chief Sustainability Officer at Procter & Gamble. “Ariel cleans impeccably in cold water and enables us to switch down the wash temperature when doing the laundry. With this we can all unite on the journey to decarbonise laundry across the entire value chain, helping the climate without compromising on cleaning performance.”
Ariel’s core purpose is to reinvent clean to drive progress, and its expanded Ambition announced today is underpinned by a wide range of other actions it is taking to ensure the interconnected sustainability challenges we all face are being addressed. These include circular packaging, responsibly sourced and less carbon intensive ingredients, and establishing an even more efficient supply chain among others. On the societal side, Ariel continues to advocate how laundry is not only a woman’s job, but the responsibility of everyone in the household.
Ariel is one of P&G’s leading brands, and the Brand Ambition announcement is part of the overall commitment from P&G for 100% of their leadership brands to enable and inspire responsible consumption by 2030 as part of the company’s Ambition 2030 sustainability goals.
To access images and other multimedia content, please visit here .
About Every Degree Makes a Difference Campaign
“Every Degree Makes a Difference” is a campaign being run by Ariel that aims to educate consumers on the benefits of turning their washing machines down and doing their laundry at lower temperatures. The campaign has been designed to educate consumers on the following key information: https://www.nationalgeographic.com/ariel-every-degree-makes-a-difference/
The Life Cycle Assessment of a fabric care detergent clearly signifies that the environmental footprint is only 40% product related versus up to 60% usage related at home when people use the washing machine (50% from heating the water, data is based on the average for European region).
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005112/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom